UniXell Biotechnology
Latest round
- Series A
Last raised
- Feb 2026
Total raised
- $21M
Investors
- 7
About UniXell Biotechnology
, trading as UniXell Biotechnology, is a developer of new generations of cell therapy drugs, focusing on the development of next-generation cell therapy drugs based on human pluripotent stem cell technology. It has an R&D centre of approximately 4,000 square meters and a GMP clean factory building. The founder, Dr. Yuejun Chen, graduated from the University of Wisconsin, Madison, and has worked at the Chinese Academy of Sciences. The company utilizes a self-developed platform for technology research and product development in the field of stem cell therapy. The platform is a technology platform for human pluripotent stem cell preparation, culture, differentiation and gene editing. The company currently has five product pipelines under research and development. The R&D pipeline therapeutic areas include neurodegenerative diseases, rare diseases and tumors. The company generates revenue by providing its proprietary cell therapy products and services.
Who invested in UniXell Biotechnology
7 investors across 5 rounds
See all investors in UniXell Biotechnology
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about UniXell Biotechnology
Who invested in UniXell Biotechnology?
UniXell Biotechnology has 7 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has UniXell Biotechnology raised?
UniXell Biotechnology has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did UniXell Biotechnology last raise money?
UniXell Biotechnology's most recent round on record is a Series A, in Feb 2026.
What does UniXell Biotechnology do?
, trading as UniXell Biotechnology, is a developer of new generations of cell therapy drugs, focusing on the development of next-generation cell therapy drugs based on human pluripotent stem cell technology.
Where is UniXell Biotechnology headquartered?
UniXell Biotechnology is headquartered in Shanghai, China.
Which VCs invest in companies like UniXell Biotechnology?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at UniXell Biotechnology's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like UniXell Biotechnology? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.